Sanofi and Regeneron have been battling with PCSK9 rival Amgen over patents for their cholesterol drugs for years, with Amgen at one point securing an injunction against sales of the partners’ Praluent. Now, Sanofi and Regeneron have persuaded a judge that
read moreSterile drugs are susceptible to microbial contamination and so the water used to make ingredients need to be clean. An Indian API maker has been given that message loud and clear in a warning letter issued by the FDA. More:
read moreA 10-year wait obviously didn’t discourage Kyowa Kirin from changing the FDA’s mind for its add-on Parkinson’s therapy. Rejected by the FDA in 2008, the pharma’s Nourianz has finally secured a U.S. go-ahead, six years after it was launched in
read moreWall Street analysts have concluded Amgen’s $13.4 billion purchase of psoriasis drug Otezla represents an overpayment of at least $2 billion. But with its Enbrel sales force, Amgen may be equipped to make the deal a success, they add. More:
read moreAstraZeneca and GlaxoSmithKline have long locked horns in their battle for respiratory supremacy with the latter holding the clear advantage in triple-drug inhaler market. Another round of positive data for its combo candidate could give AZ a leg up. More:
read moreGSK is now responsible for all development, regulatory and commercialisation activities and costs. More: Ionis to license hep B programme to GSK Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals